Arrhythmias associated with myocardial ischaemia and infarction

The intention of this review has been to summarise the current state of knowledge regarding the arrhythmias induced by myocardial ischaemia and infarction. Both clinical and experimental aspects were considered. There has been some progress toward understanding the electrophysiological mechanisms responsible for the genesis of such arrhythmias but understanding is far from complete. We are still unable to trace the sequence of events which begin with the electrophysiological changes induced in cells by ischaemia and progress through macromechanisms such as re-entry, automaticity, etc., to the final arrhythmia. Exactly how the changes in individual cells translate into the macromechanisms is not known. Similarly, which macromechanism actually operate, and to what extent, is not known.We have very little information regarding the biochemical events responsible for the changes in intracellular potential seen with ischaemia. Similarly, we do not know whether arrhythmogenic mediators are involved in such a process. We have a fairly complete catalogue of the changes in biochemistry induced by ischaemia, but at the moment it is difficult to find causal relationships between such changes and ischaemia-induced disturbances in electrophysiology.Finally, we are in possession of a catalogue of drugs which may reduce the arrhythmias induced by ischaemia and infarction (both clinically and experimentally), but have no clear direction as how to develop the ideal antiarrhythmic (antifibrillatory) drugs.     

Carboxypeptidase digestion of human chorionic gonadotropin

Native human chorionic gonadotropin (hCG) was resistant to carboxypeptidase digestion even in the presence of urea. Isolated alpha subunit of the hormone (hCG-alpha), though unreactive to enzyme treatment in the absence of denaturant, released up to four amino acid residues from the C-terminus on incubation with a mixture of carboxypeptidases A and B in urea. While an hCG-alpha product which lacked Ser-92 recombined completely with intact hCG-beta, hCG-alpha from which Ser-92 recombined completely with intact hCG-beta, hCG-alpha from which Ser-92 and Lys-91 were removed showed only partial recombination. The two recombinants were devoid of any in vivo biologic activity, but retained some of the immunologic activity of the native recombinant. These findings indicate that the integrity of the C-terminal residue of serine in hCG-alpha is essential for the expression of in vivo biologic activity of the native hormone.